Disease Info Card

Liver Cirrhosis, Experimental

Information about Liver Cirrhosis, Experimental: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Liver Cirrhosis, Experimental

Most recent studies have shown that Liver Cirrhosis, Experimental shares some biological mechanisms with aortic-aneurysm-thoracic, biliary-cirrhosis, cholestasis, choline-deficiency, drug-induced-liver-injury, fatty-liver, fibrosis, hepatic-fibrosis, hepatitis, hypertension-portal, hypertensive-disease, inflammation, injury-to-liver, liver-carcinoma, liver-cirrhosis, liver-damage, liver-diseases, liver-regeneration-disorder, steatosis, toxic-effect-of-carbon-tetrachloride.

Among the many pathways, these few ones have gauged particular interests from scientists studying Liver Cirrhosis, Experimental, and have been seen in publications frequently: Angiogenesis, Cell Activation, Cell Cycle, Cell Death, Cell Proliferation, Excretion, Glomerular Filtration, Hepatic Stellate Cell Activation, Hepatocyte Proliferation, Inflammatory Response, Liver Regeneration, Localization, Natriuresis, Pathogenesis, Regeneration, Secretion, Transport, Vasoconstriction, Vasodilation, Wound Healing

Quite a number of genes have been found to play important roles in Liver Cirrhosis, Experimental, such as AGT, ALB, DES, EDN1, FN1, FUT1, HGF, IGF1, IL6, MMP2, NOS2, NOS3, SLC17A5, SYNM, TGFB1, TIMP1, TNF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.